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ABSTRACT
Esophageal cancer remains a poor prognosis cancer due to advanced stage of 
presentation and drug resistant disease. To understand the molecular mechanisms 
influencing response to chemotherapy, we examined genes that are differentially 
expressed between drug sensitive, apoptosis competent esophageal cancer cells 
(OE21, OE33, FLO-1) and those which are more resistant and do not exhibit apoptosis 
(KYSE450 and OE19). Members of the ISG15 (ubiquitin-like) protein modification 
pathway, including UBE2L6 and ISG15, were found to be more highly expressed in the 
drug sensitive cell lines. In this study, we evaluated the contribution of these proteins 
to the response of drug sensitive cells. Depletion of UBE2L6 or ISG15 with siRNA 
did not influence caspase-3 activation or nuclear fragmentation following treatment 
with 5-fluorouracil (5-FU). We assessed autophagy by analysis of LC3II expression 
and Cyto-ID staining. Depletion of either ISG15 or UBE2L6 resulted in enhanced 
endogenous autophagic flux. An increase in autophagic flux was also observed 
following treatment with cytotoxic drugs (5-FU, rapamycin). In ISG15 depleted cells, 
this increase in autophagy was associated with improved recovery of drug treated 
cells. In contrast, UBE2L6 depleted cells, did not show enhanced recovery. UBE2L6 
may therefore influence additional targets that limit the pro-survival effect of ISG15 
depletion. These data identify UBE2L6 and ISG15 as novel inhibitors of autophagy, 
with the potential to influence chemosensitivity in esophageal cancer cells.
INTRODUCTION
Cancers of the esophagogastric region are highly 
malignant tumours with European 1-year and 5-year 
survival rates of 40 % and 12 % respectively, according 
to the 2015 EUROCARE-5 study [1]. The current gold 
standard of treatment involves both chemotherapeutic 
intervention and surgery to remove the primary tumour 
[2, 3]. However, in the long term, this approach is 
often unsuccessful due to the survival of drug resistant 
disseminated cells that can recover from treatment [4]. 
There is therefore a major need to develop new approaches 
to treat both primary and recurrent esophageal cancer.
A highly significant factor contributing to drug 
resistance is the inactivation of apoptosis in cancer 
cells. We have previously shown that 5-fluorouracil and 
cisplatin induce apoptotic cell death in drug sensitive 
OE21 and OE33 esophageal cancer cell lines. In contrast, 
treatment of apoptosis resistant cell lines KYSE450 and 
OE19 results in induction of autophagy and subsequent 
recovery following withdrawal of the drug [5]. Autophagy 
is a highly conserved process that catabolises and recycles 
damaged organelles and protein complexes. This process 
can be triggered when a cell is exposed to stressful 
conditions such as nutrient deprivation, cellular damage 
and hypoxia [6]. In the case of a healthy cell, this can have 
a positive, protective function. However, an established 
cancer cell can exploit this process to facilitate survival 
when treated with a cytotoxic agent, resulting in tumour 
cell resistance and cancer recurrence [7, 8].
We undertook gene expression analysis of the 
sensitive and resistant esophageal cancer cells lines in 
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order to identify patterns of gene expression associated 
with cellular response to cytotoxic drug. We found that 
several members of the ISG15 conjugation pathway are 
upregulated in apoptosis & autophagy competent cell 
lines (OE21 and OE33) and downregulated in cell lines 
which are apoptosis resistant and which respond to drug 
treatment by inducing autophagy only (KYSE450 and 
OE19).
Interferon Stimulated Gene 15 (ISG15) is a 15 kD 
ubiquitin-like protein modifier which can be conjugated 
to protein substrates in order to modify their functions. 
Stimulation by Type I Interferons (IFN α or β) activates 
the transcription of over 2000 Interferon Stimulated Genes 
(ISGs) (reviewed in [9, 10, 11]). Among these ISGs are 
three key enzymes: UBE1L (ISG15 specific E1 activating 
enzyme), UBE2L6 (ISG15/ubiquitin E2 conjugating 
enzyme) and HERC5 (ISG15 specific E3 ligase). In a 
mechanism similar to ubiquitination, ISG15 is conjugated 
to targets via the sequential co-operation of these E1, 
E2 and E3 enzymes. Finally, USP18 (an ISG15 specific 
isopeptidase enzyme) can reverse ISG15 conjugation of 
target proteins.
Over 300 substrates for ISG15 modification 
have been reported. These include existing and newly 
synthesised proteins involved in proliferation, chromatin 
remodelling, cell cycle regulation and innate immune 
system activation [12, 13, 14]. The ISG15 pathway 
has been found only in higher eukaryotic cells, indicating 
specialised functions [15]. Importantly, UBE2L6 is not 
restricted to ISGylation as it can also function as an 
E2 enzyme in the conjugation of ubiquitin to target 
proteins [16].
In this study, we have identified ISG15 and UBE2L6 
as negative regulators of autophagy in esophageal cancer 
cells. As the effects of UBE2L6 siRNA on autophagy are 
consistent with ISG15 siRNA, it is possible that UBE2L6 
influences autophagy by promoting direct conjugation 
of ISG15 to targets which directly or indirectly regulate 
autophagy.
It is notable however, that the effects of ISG15 
and UBE2L6 depletion on overall survival are different. 
This is perhaps unsurprising as UBE2L6 can facilitate 
ubiquitination, which will expand its repertoire of targets 
and thus impact its overall biological effect.
RESULTS
Proteins associated with the ISG15 conjugation 
pathway are upregulated in apoptosis competent 
cell lines
We previously evaluated the response of four 
esophageal cell lines to drug treatment [5]. Two cell 
lines (OE21 and OE33) exhibited both apoptosis and 
autophagy and are relatively drug sensitive. In contrast, 
two cell lines (KYSE450 and OE19) fail to undergo 
apoptosis in response to drug treatment and instead, 
respond by inducing autophagy alone. These cell lines 
are more drug resistant and can recover following drug 
withdrawal. We reasoned that these two groups may differ 
in the genes that they constitutively express, and this may 
affect their response to cytotoxic stress. We conducted 
Affymetrix gene array analysis of all four cell lines in 
triplicate. The array hybridisation and bioinformatics 
was carried out by Almac Diagnostics (www.almac.
com; methods are included in Supplementary Figure 1). 
We initially identified a list of genes that were common 
to group A (apoptosis & autophagy cells) and a separate 
list of genes that were common to group B (autophagy 
only cells). Each group contained one adenocarcinoma 
and one squamous cell carcinoma cell line. Genes which 
differed due to histological subtype were eliminated 
at this stage. We then looked for genes that are always 
expressed in the same direction in Group A (apoptosis & 
autophagy competent) but differentially expressed in 
Group B. 260 genes had more than a three-fold difference 
in the level of expression between the apoptosis competent 
(OE21, OE33) and apoptosis incompetent, autophagy only 
(KYSE450 and OE19) cell lines. Biological data on these 
genes was assimilated and STRING analysis was used to 
look for associated protein networks. One of the nodes 
identified by STRING included the most differentially 
expressed gene (UBE2L6; 17-fold differential) and several 
other members of the ISGylation network including ISG15 
itself (Figures 1A and 1B). We therefore selected UBE2L6 
and ISG15 for further analysis. Differential expression in 
the cell lines was confirmed by Western blot. These data 
confirm a significant difference in UBE2L6 and ISG15 
protein expression between the apoptosis competent and 
apoptosis incompetent cell lines (Figures 1C and 1D).
siRNA targeted against UBE2L6 or ISG15 has 
no influence on the induction of apoptosis
We initially examined whether the expression levels 
of UBE2L6 or ISG15 were important for the induction 
of apoptosis in OE21 cells treated with 5-fluorouracil 
(5-FU). Activation of caspase-3, a standard biochemical 
marker of apoptosis, was quantitated by flow cytometry 
and morphological features of cell death examined, in 
drug treated cells, in the presence or absence of UBE2L6 
or ISG15 siRNA (Figure 2).
siRNA mediated depletion of UBE2L6 was 
confirmed by Western blot (Figure 2A). OE21 cells are 
relatively drug sensitive and activate caspase-3 in response 
to treatment with 5-FU. OE21 cells with UBE2L6 siRNA 
alone or in the presence of 5-FU (30 μM) for 48 hr (upper 
and lower right panels), induced similar levels of activated 
caspase-3 as the scrambled controls (upper and lower left 
panels). Data from triplicate experiments is presented as 
“% caspase positive cells” to the right. Examination of 
cell morphology also identified similar levels of apoptotic 
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nuclear fragmentation in UBE2L6 depleted and scrambled 
control cells treated with 5-FU (Figure 2C lower right and 
left panels respectively, arrows).
Activation of caspase-3 was also examined in ISG15 
depleted cells. siRNA mediated depletion of ISG15 was 
confirmed by Western blot (Figure 2D). ISG15 depleted 
cells showed similar levels of active caspase-3 to 
scrambled control cells in the absence (Figure 2E upper 
panels) or presence of 5-FU (30 μM) (Figure 2E lower 
panels). Data from triplicate experiments is presented to 
the right as “% caspase-3 positive cells”. Examination of 
cell morphology also identified similar levels of apoptosis 
in ISG15 depleted and scrambled control cells treated with 
5-FU (Figure 2F arrows).
A colony formation assay was performed to evaluate 
the ability of these cells to recover from treatment with 
Figure 1: Proteins associated with the ISG15 conjugation pathway are upregulated in apoptosis competent cell lines. 
A. String analysis of differentially expressed proteins that intersect with ISG15 (www.string.org). This is the confidence view. Stronger 
associations are represented by thicker lines. B. Genes which show at least a 3-fold differential in expression and that are involved in the 
ISG15 conjugation network are illustrated in the table. C. Differential expression of UBE2L6 and D. ISG15 were confirmed by Western 
blot. Bands were quantified and normalised to β-actin.
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Figure 2: siRNA depletion of UBE2L6 or ISG15 has no effect on the induction of apoptosis in OE21 cells treated with 
5-fluorouracil (5-FU). A. Gene specific siRNA (20 nM), was used to deplete UBE2L6 expression. Silencing was confirmed by Western 
blot in the presence and absence of 5-FU. B. UBE2L6 depleted and scramble control cells were treated with 5-FU (30 μM) for 48 hr and 
were analysed for levels of active caspase-3 by flow cytometry. Data from three independent experiments is presented as ‘% caspase positive 
cells’. C. Morphological analysis (40x magnification) of scramble control siRNA (left panels) and UBE2L6 siRNA (right panels) cells in the 
absence (upper panels) or presence of 5-FU (lower panels) (arrows indicate nuclear fragmentation). D. siRNA was used to deplete ISG15 
expression and silencing was confirmed by Western blot in the presence and absence of 5-FU. All bands were quantified and normalised to 
β-actin. E. ISG15 depleted and scramble control cells were treated with 5-FU for 48 hr and were analysed for levels of active caspase-3 by flow 
cytometry. Data from three independent experiments is presented as ‘% caspase positive cells’. F. Morphological analysis (40x magnification) 
of scramble control siRNA (left panels) and ISG15 siRNA (right panels) cells in the absence (upper panels) and presence of 5-FU (lower 
panels) (arrows indicate nuclear fragmentation). G. Following drug removal, a colony formation assay was carried out to determine the ability 
of UBE2L6 depleted (i) or ISG15 depleted (ii) cells to recover, relative to scramble control cells. Colonies were stained using Rapi-diff and 
quantified using the Odyssey Infra-red imaging system. Triplicate data is presented in the graph as integrated intensity ± SEM (**p < 0.01).
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5-FU. In cells transfected with UBE2L6 siRNA, there 
was no significant difference in the recovery of cells 
following 5-FU treatment [Figure 2G (i)]. In contrast, cells 
transfected with ISG15 siRNA demonstrated a significant 
rescue from 5-FU relative to scrambled controls (**p = 
0.0089) [Figure 2G (ii)] (data is presented as integrated 
intensity and colonies shown are representative of three 
replicates).
ISG15 silencing with siRNA promotes 
endogenous and induced autophagic flux
The enhanced recovery of cells with ISG15 siRNA 
suggested that ISG15 expression may be impeding a 
survival pathway. Therefore, the effect of ISG15 siRNA on 
endogenous and induced autophagy was assessed. For all 
autophagy assays, cells were treated with 5-FU (30 μM) 
for 24 hr and then replenished with drug free media for 
a further 24 hr. As shown in Figure 3A, analysis of LC3 
II (an autophagosome marker) by Western blot revealed 
a clear increase in LC3 II accumulation in untreated 
cells with ISG15 siRNA alone when compared with 
untransfected and scrambled controls. LC3 II induction by 
5-FU was also further enhanced by ISG15 siRNA (Figure 
3B middle lane).
The effect of ISG15 siRNA on autophagy was also 
quantified using an additional assay, the Cyto-ID autophagy 
detection kit, which specifically labels autophagosomes. As 
shown in Figure 3C, ISG15 siRNA significantly increased 
5-FU induced Cyto-ID fluorescence confirming enhanced 
autophagosome accumulation (red overlay) beyond 
scramble control (blue overlay) (**p = 0.0016). Data 
from three independent experiments is presented as mean 
fluorescence intensity (MFI) to the right.
Analysis of cellular morphology showed vesicle 
accumulation in cells treated with 5-FU (Figure 3D upper 
right panel, arrowheads). When ISG15 is depleted by 
siRNA, vesicle accumulation is further enhanced (Figure 
3D lower left and right panels, arrowheads).
The entire autophagic process, from sequestration 
to degradation is referred to as autophagic flux. LC3 II 
accumulation may be a consequence of either increased 
autophagy initiation or a block in autophagosome turnover. 
Therefore, to differentiate between induction and vesicle 
accumulation due to a failure in turnover, cells were 
pre-treated with chloroquine to block lysosome function 
and autophagosome turnover. Any LC3 II accumulation 
beyond that observed with chloroquine alone is then 
attributed to enhanced autophagy initiation [17].
The effect of ISG15 siRNA on flux was assessed 
by 2 hr pre-treatment of cells with chloroquine (10 
μM) followed by treatment with 5-FU for 24hr, which 
was followed by an additional 24 hr recovery in drug 
free medium. As shown in Figure 3E, treatment of 
untransfected or scrambled control cells with chloroquine 
alone showed LC3 II accumulation (when compared to 
control levels in Figure 3A), which was further enhanced 
by ISG15 siRNA (lane 2). In cells treated with 5-FU in 
the presence of chloroquine (Figure 3F), LC3II levels 
were also further enhanced by ISG15 siRNA, indicating 
elevated autophagic flux.
The Cyto-ID assay was used to confirm these 
findings (Figure 3G). A significant increase in fluorescence 
is observed in ISG15 depleted cells treated with a 
combination of 5-FU and chloroquine (red overlay) when 
compared to scramble controls (blue overlay) (***p < 
0.0001). Data from three independent experiments is 
presented as mean fluorescence intensity (MFI) to the right.
Analysis of cell morphology indicated extensive 
accumulation of vesicles in the presence of both 
chloroquine and a combination of 5-FU & chloroquine 
in ISG15 depleted cells (Figure 3H lower left and right 
panels, arrowheads). Collectively, these data suggest that 
ISG15 siRNA is initiating autophagy rather than impeding 
autophagosome turnover. Similar effects of ISG15 siRNA 
on induced autophagy were observed with rapamycin and 
valproic acid (Supplementary Figure 2).
An additional apoptosis competent esophageal 
cancer cell line (FLO-1), expressing the ISGylation 
pathway was also evaluated. Depletion of ISG15 was 
confirmed by Western blot (Supplementary Figure 3A) 
and resulted in elevated LC3 II in both untreated and 
5-FU treated cells, when compared to scramble controls 
(Supplementary Figure 3B). The Cyto-ID assay was used 
to confirm that ISG15 siRNA is also initiating autophagy 
in this cell line, with enhanced fluorescence observed 
in ISG15 depleted cells treated with either chloroquine 
alone [Supplementary Figure 3C (i)] (red overlay) (**p 
= 0.0046) or combined with 5-FU [Supplementary 
Figure 3C (ii)] (red overlay) (**p = 0.0038) relative to 
scrambled controls (blue overlays). Depletion of ISG15 
also enhanced the recovery of FLO-1 cells, relative to 
scrambled controls (Supplementary Figure 3D).
UBE2L6 siRNA promotes endogenous autophagy 
induction
Our data thus far has suggested that ISG15 
can influence autophagy. If UBE2L6 is required for 
conjugating ISG15 to substrate proteins, then UBE2L6 
would be expected to influence autophagy in a similar 
manner to ISG15.
To evaluate the contribution of UBE2L6 to 
autophagy, gene expression was depleted by siRNA and loss 
of UBE2L6 protein was confirmed by Western blot (Figure 
4A). UBE2L6 siRNA alone [Figure 4B lane 2 (without 
drug)] increased the level of LC3 II relative to controls 
(lanes 1 and 3). Chloroquine treatment (10 μM) alone 
increased LC3 II in scrambled and untransfected control 
cells (lanes 4 and 6) and this is significantly enhanced by 
UBE2L6 siRNA (lane 5), suggesting that UBE2L6 also 
influences autophagy initiation rather than turnover.
The effect of UBE2L6 siRNA on autophagy was 
also quantitated using the Cyto-ID assay. As shown in 
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Figure 3: ISG15 silencing with siRNA promotes both endogenous and induced autophagic flux. For all autophagy assays - 
OE21 cells were treated for 24 hr and allowed to recover for an additional 24 hr in drug free medium. The effect of ISG15 siRNA (middle 
lanes) on A. endogenous LC3 II and B. 5-FU-induced (30 μM) LC3 II, relative to untransfected (left lanes) and scrambled control (right 
lanes) was assessed by Western blot. C. Cyto-ID autophagy detection kit was used to assess autophagosome formation by ISG15 siRNA alone 
(orange overlay) relative to scrambled (green overlay) or untreated cells (grey filled histogram). 5-FU-induced autophagy was assessed in 
ISG15 depleted cells (red overlay) relative to scramble control (blue overlay) (**p < 0.005) or untransfected (black overlay) cells. D. Analysis 
of vesicle accumulation (black arrowheads) in scrambled (upper panels) and ISG15 siRNA (lower panels) cells, without (left panels) and with 
5-FU (right panels) (40x magnification). E. Autophagic flux was assessed by measuring LC3 II levels in untransfected (left lanes), scrambled 
control (right lanes) and ISG15 siRNA (middle lanes) cells following 24 hr treatment with chloroquine (10 μM) alone or F. in combination 
with 5-FU (30 μM). LC3 II levels were normalised to β-actin and presented as integrated intensities. Western blots shown in parts A, B, E & 
F are all from the same blot G. Cyto-ID assay was used to assess 5-FU-induced autophagic flux in ISG15 depleted (red overlay), scramble 
control (blue overlay) (***p < 0.0001) and untransfected (green overlay) cells, treated with 5-FU and chloroquine. H. Induction of vesicles 
was confirmed by morphological analysis (black arrowheads, 40x magnification) following transfection with scrambled control (upper panels) 
or ISG15 siRNA (lower panels) in cells treated with chloroquine alone (left panels) or in combination with 5-FU (right panels).
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Figure 4C, UBE2L6 siRNA significantly increased Cyto-
ID fluorescence (orange overlay) relative to scrambled 
control (green overlay) (**p = 0.0012). Treatment of 
UBE2L6 depleted cells with chloroquine achieved a 
further increase (red overlay) relative to the scrambled 
control (blue overlay) (***p = 0.0002). Data from 
three independent experiments is presented as mean 
fluorescence intensity (MFI) to the right. Collectively, 
these data indicate that UBE2L6 siRNA can promote 
endogenous autophagy induction, as observed with ISG15.
UBE2L6 siRNA enhances autophagy induction 
by 5-FU
We then assessed if UBE2L6 siRNA could enhance 
autophagy induction by a chemotherapeutic agent. OE21 
cells were treated with 5-FU (20 μM) in the presence 
or absence of chloroquine (10 μM) for 24hr. As shown 
by Western blot in Figure 5A, UBE2L6 siRNA further 
enhanced LC3 II induction by 5-FU, indicating that 
UBE2L6 siRNA increases 5-FU induced autophagy, 
similar to ISG15. Examination of morphology of 5-FU 
treated cells showed enhanced vesicle formation in the 
presence of UBE2L6 siRNA (Figure 5B right panel, 
arrowheads).
Cyto-ID was also used to quantitate autophagosome 
formation induced by 5-FU (Figure 5C). In the presence 
of UBE2L6 siRNA (red overlay), 5-FU-induced 
autophagosome levels were greater than either 5-FU 
alone (black overlay) (***p < 0.0001) or scrambled 
controls (blue overlay) (***p < 0.001). Data from three 
independent experiments is presented as MFI to the right. 
Similar results were obtained for other autophagy inducers 
including rapamycin (Supplementary Figure 4), lithium 
chloride and valproic acid (not shown).
Effects on autophagic flux were assessed by 
Western blot. The combination of chloroquine and 5-FU, 
in untransfected or scrambled control cells, induced an 
Figure 4: UBE2L6 siRNA promotes endogenous autophagy induction. A. Silencing of UBE2L6 by siRNA (20 nM) was 
confirmed by Western blot. B. Induction of autophagy was evaluated by Western blot analysis of LC3 II levels normalised to β-actin for 
untreated (lanes 1-3) or 24 hr chloroquine (10 μM) treated cells (lanes 4-6) in the presence of UBE2L6 siRNA (lanes 2 & 5). C. Cyto-ID 
was used to assess autophagosome formation by UBE2L6 siRNA alone (orange overlay) relative to scrambled (green overlay) or untreated 
(grey filled peak). Flux was analysed in UBE2L6 siRNA cells (red overlay) and compared with scrambled siRNA control (blue overlay). 
Data from three independent experiments is presented to the right as mean fluorescence intensities ± SEM (**p < 0.005, ***p < 0.0005).
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Figure 5: UBE2L6 siRNA enhances 5-FU-induced autophagic flux. A. The effect of UBE2L6 siRNA (middle lane) on autophagy 
induction relative to untransfected or scrambled controls (left and right lanes respectively) following treatment with 5-FU (20 μM) for 24 
hr was assessed by Western blot. B. Morphological analysis (40x magnification) compares vesicle accumulation (black arrowheads) in 
scrambled siRNA control cells (left panel) to UBE2L6 siRNA cells (right panel) following treatment with 5-FU. C. Cells treated with 
5-FU (black overlay) were stained with Cyto-ID. Autophagosome formation was assessed in drug treated cells with UBE2L6 siRNA (red 
overlay), relative to scramble controls (blue overlay). Data from three independent experiments is presented as mean fluorescence intensity 
± SEM to the right (***p < 0.0001). D. To assess flux, cells were treated with chloroquine (10 μM) in combination with 5-FU for 24 hr in the 
presence of either scrambled (lane 3) or UBE2L6 siRNA (lane 2). LC3 II levels were normalised to β-actin. Western blots shown in parts A 
& D are from the same blot E. Morphology of cells treated with a combination of 5-FU and chloroquine was compared in scrambled control 
cells (left panel) and UBE2L6 siRNA cells (right panel). Autophagic vesicles are indicated by black arrowheads (40x magnification). F. 
The effect of UBE2L6 siRNA on autophagic flux was assessed by treating cells with either 5-FU (orange overlay) or chloroquine (black 
overlay) alone or a combination of both (green overlay) in the absence (blue overlay) or presence (red overlay) of UBE2L6 siRNA. Mean 
Fluorescence Intensities of three independent experiments are shown to the right (***p < 0.0001).
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increase in LC3 II above that observed with 5-FU alone 
(see Figure 5A ), however the levels of LC3 II were 
further increased in UBE2L6 depleted cells (Figure 5D). 
Morphology also confirmed a further induction of vesicles 
in UBE2L6 depleted cells, when compared to scrambled 
control cells treated with a combination of chloroquine 
and 5-FU (Figure 5E right panel, arrowheads). Flux 
was also assessed using Cyto-ID staining. Chloroquine 
(black overlay) or 5-FU alone (orange overlay) caused 
an increase in fluorescence above untreated cells (grey 
filled peak) (Figure 5F). The combination of chloroquine 
and 5-FU (green overlay) resulted in autophagosome 
accumulation in excess of either chloroquine or drug 
alone, which was further enhanced by UBE2L6 siRNA 
(red overlay) relative to scrambled controls (blue overlay) 
(***p < 0.0001). Data from three independent experiments 
is presented as MFI to the right. The effect of UBE2L6 
siRNA on autophagy induction was also confirmed 
using rapamycin (100 nM) in the presence or absence of 
chloroquine (10 μM) (Supplementary Figure 4).
The effect of UBE2L6 was also evaluated in the 
FLO-1 cell line. Silencing of UBE2L6 with siRNA was 
confirmed by Western blot (Supplementary Figure 5A). 
UBE2L6 siRNA alone increased the levels of LC3 II 
relative to controls (Supplementary Figure 5B, lanes 
1-3). 5-FU treatment increased LC3 II in scrambled and 
untransfected cells (lanes 4 and 5) and this was enhanced 
by UBE2L6 siRNA (lane 6), suggesting that UBE2L6 
influences 5-FU-induced autophagy in this cell line. The 
increase in LC3 II in UBE2L6 depleted cells treated with 
a combination of 5-FU and chloroquine (Supplementary 
Figure 5C, lane 6) suggests that UBE2L6 also influences 
initiation rather than turnover in the FLO-1 cells.
The Cyto-ID assay also demonstrates a significant 
difference in autophagosome accumulation in FLO-1 cells 
with depleted UBE2L6 (orange overlay) when compared 
to scrambled controls (green overlay) (Supplementary 
Figure 5D) (**p = 0.0013). This elevation of autophagy 
was also evident in response to 5-FU (Supplementary 
Figure 5E) (**p = 0.0075) and again in cells treated with 
a combination of 5-FU and chloroquine (Supplementary 
Figure 5F) (***p < 0.0001) – indicating elevated 
autophagic flux in both untreated and 5-FU treated FLO-1 
cells (Supplementary Figure 5A-5F). Analysis of recovery 
of FLO-1 cells following 5-FU treatment, found no 
difference in UBE2L6 depleted cells relative to scrambled 
controls (Supplementary Figure 5G).
These data collectively suggest that UBE2L6 can 
negatively regulate the initiation of endogenous autophagy 
and autophagy induced by a range of other cytotoxic 
agents. This is consistent with the effect of ISG15 siRNA 
and suggests that UBE2L6 may regulate autophagy 
induction via the ISG15 pathway.
Induction of autophagy by ISG15 siRNA is associated 
with enhanced recovery in both OE21 and FLO-1 cells. In 
contrast, UBE2L6 depletion does not protect either cell line 
from 5-FU – despite clear induction of autophagy. UBE2L6 
may therefore have other substrates or targets that limit any 
protective effects of the induced autophagy.
Evaluation of mRNA expression in tumours
We examined publicly available databases to look 
for a potential biological significance of UBE2L6 or 
ISG15 transcript expression. The Cancer Genome Atlas 
(TCGA) had sequence data – but limited expression data 
for esophageal or gastric cancer. We then looked at a 
gastric cancer database that has been assembled recently 
from several sources and includes studies using the same 
arrays that we used in our initial analysis of the esophageal 
cell lines (HGU133) [18]. This combined database is 
publicly available at:
http://kmplot.com/analysis/index.php?p=service& 
cancer=gastric.
While this is not the same tissue type as our study, it 
is a similar type of cancer in terms of origin and treatment. 
Expression of UBE2L6 / UBCH8 (Affy ID201649_at) was 
analysed in 876 patients. Patients were split according 
to median expression and there was no restriction on 
subtype. Kaplan Meier overall survival (OS) analysis is 
presented in Supplementary Figure 6. Higher expression 
of UBE2L6 was associated with better overall survival 
(hazard ratio (HR) = 0.8, P= 0.02) (Supplementary Figure 
6A). In our cell lines, this would be associated with 
apoptosis competency and repression of autophagy. We do 
not know if this is linked to outcome in patients. UBE2L6 
expression can be up regulated by Type I interferons and 
may also be an indication of immune cell activation. 
ISG15 expression was also analysed and while a similar 
trend was apparent, this did not achieve significance 
(P=0.094) (Supplementary Figure 6B).
DISCUSSION
In this study, we have identified ISG15 and UBE2L6 
as negative regulators of autophagy in esophageal cancer 
cells. This suggests that ISG15 may be a key ubiquitin-
like modifier of autophagy and that its conjugation to 
substrates is likely to involve the E2 activity of UBE2L6. 
Ubiquitin and other ubiquitin-like conjugation systems 
are a well-known feature of autophagy regulation and 
overall regulation of proteostasis. In contrast, modification 
of proteins with ISG15 is less well understood and has 
been largely associated with innate immune defence 
mechanisms. However, recent studies have highlighted 
a potential link to autophagy as two key regulators of 
autophagy or mitophagy (Beclin 1 and Parkin) have now 
been identified as targets of ISGylation.
Autophagy targets
Type I IFN has been reported to induce ISGylation 
of Beclin 1 at several lysine residues [19]. This protects 
BECN1 from ubiquitination at Lys63 and inhibits PI3KC 
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kinase activity. As this suppresses autophagy it would 
be consistent with our data, which imply a negative 
regulatory role for both UBE2L6 and ISG15 in autophagy. 
These observations by Xu et al were dependent on 
exogenous stimulation of the ISG15 pathway by Type 
I interferon. This treatment will upregulate many new 
proteins and any of these may be subject to ISGylation. 
In our study, the ISG15 pathway was investigated under 
conditions of endogenous upregulation. It is possible, 
however, that overlapping pathways and targets are 
involved in both models. Our study also provides the first 
evidence for involvement of UBE2L6 whereas the Xu et al 
study highlights the opposing role of USP18, as a positive 
regulator of autophagy. Together these studies support a 
key role for this pathway in autophagy regulation. Another 
study has reported that the E3 ligase Parkin, an important 
regulator of mitophagy, is also modified by ISGylation. 
Parkin was shown to be modified when ISGylation 
components were overexpressed or when cells are treated 
with type I IFN, LPS or other selected drugs. ISGylation 
at Lys-349 and Lys 369 was reported to enhance Parkins 
E3 ligase activity [20].
UBE2L6, ISG15 and cancer
Aberrant expression of UBE2L6 or other members 
of the ISGylation system have been reported in various 
cancers [21]. Significant upregulation of UBE2L6 was 
reported in prostate cancer and esophageal squamous 
cell carcinoma when compared to corresponding non-
malignant tissues [22, 23]. ISG15 expression was also 
associated with differentiation grade and metastasis 
in Hepatocellular carcinoma [24] and had prognostic 
value in esophageal squamous cell carcinoma patients, 
particularly those who consume alcohol [25]. In 
nasopharyngeal cancer, high ISG15 correlated with 
frequent local cancer recurrence and shorter overall 
survival [26]. In pancreatic cancer, ISG15 was secreted 
by tumour associated macrophages and promoted cancer 
stem cell renewal and invasiveness [27]. We interrogated 
a publically available database to see if we could identify 
a relationship between expression of UBE2L6 or ISG15 
and overall survival in gastric cancer. Expression of 
UBE2L6 was significantly associated with better survival 
in this cohort. It would be useful to conduct further IHC 
analysis on patient tissue – to establish whether this 
expression is primarily in the tumour tissue or also in 
stromal or immune infiltrating cells.
ISGylation and therapeutic response
A previous study evaluated the effects of silencing 
either ISG15 or UBE2L6 on drug sensitivity in breast 
cancer cells. They reported a significant decrease in 
sensitivity to camptothecin (CPT) when either ISG15 or 
UBE2L6 were silenced. They also observed a reduction in 
the levels of ISG15 in a number of drug resistant cancer 
cells lines suggesting that ISG15 expression in tumours 
could be a factor affecting CPT sensitivity in these tumour 
cells [28]. In our study we found that while depletion of 
both IGS15 and UBE2L6 elevates autophagy – only those 
esophageal cancer cells with ISG15 knockdown showed a 
decrease in sensitivity to 5-FU, consistent with the effects 
of ISG15 silencing reported by Desai et al. In contrast, 
sensitivity of esophageal cells to 5-FU was unaffected by 
UBE2L6 knockdown. While we do not know the reason 
for this – it is clear from other studies that UBE2L6 can 
also act as an E2 enzyme for ubiquitin. The ubiquitination 
and stability of p21 has been reported to be mediated by 
UBE2L6 or UBCH7 and the E3 ubiquitin ligase p53RFP 
(p53-inducible RING-finger protein) [29]. The potential of 
UBE2L6 to influence ubiquitination of targets in a given 
cell type will therefore broaden its biological activity and 
may influence its overall effect on survival.
Potential targets in cancer cells?
Interferons are pleiotropic cytokines that interfere 
with viral replication. They induce transcription of 
more than 2000 interferon stimulated genes which 
predominantly serve to activate the immune system. A 
number of groups have now identified Type I interferons 
as autophagy inducers [30]. In recent years, it has emerged 
that autophagy plays a crucial role in the clearance of 
bacterial and viral pathogens (reviewed in [31–33]). 
Many studies have also implicated UBE2L6 and ISG15 
as critical components of the innate immune response to 
pathogen infection [34–36]. However, if expression of 
the ISG15 pathway was directly required for autophagy 
induction, we would have expected silencing of either 
UBE2L6 or ISG15 to inhibit autophagy in our cells rather 
than inducing it. Indeed, a recent study looking at enforced 
overexpression of ISG15, or Type I IFN stimulation, 
has reported that ISG15 interacts with HDAC6 and 
p62 which facilitates aggresome formation and thereby 
promotes autophagy [37]. As ISG15 has a preference 
for newly synthesised proteins [38]– this may be a way 
of eliminating viral proteins which are produced in vast 
excess following infection, as they could potentially be 
cleared by ISGylation, aggregation and autophagy.
Here, with endogenous expression in esophageal 
cancer cells, we report the opposite effect – knockdown 
of ISG15 or UBE2L6 promotes autophagy. It is important 
to consider that interferon signalling results in elevated 
expression of a vast number of genes, any of which may 
be the primary inducers of autophagy during infection. It 
is possible that the ISG15 pathway can perform a negative 
regulatory role to prevent over activation of autophagy. 
This sort of negative feedback loop is a common feature 
in immune regulation. It is also possible that endogenous 
ISGylation (as in these tumour cells) may have a different 
function in tumour cells – and distinct targets – compared 
to interferon-induced ISGylation. It is notable that, many 
of the targets identified by mass spectrometry in IFN 
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treated cells, were also constitutively expressed and 
involved in processes such as stress response, metabolism, 
chromatin remodelling or RNA processing [12].
We currently do not know the mechanism by which 
the ISGylation pathway may be regulating autophagy and 
it is possible that several targets are involved. Combined 
proteomic studies have identified at least 300 proteins that 
are targeted by ISGylation [12, 14, 39], although only a 
fraction have been experimentally validated as substrates, 
with known effects of ISGylation [40]. ISGylation may 
modulate stability, activity or interaction with other 
proteins. It has been suggested that ISGylation could 
increase the stability of substrates as it opposes poly-
ubiquitination [41]. Silencing of UBE2L6 or ISG15 by 
siRNA may therefore lead to increased poly-ubiquitination 
and degradation of a negative regulator(s) of autophagy. 
Further studies must be carried out to identify the 
substrates and primary mechanisms involved in autophagy 
regulation.
In conclusion, this data has shown that the ISG15 
pathway may play a role in chemosensitivity by regulating 
autophagy and survival. It is notable that this pathway is 
not critical to normal cells and is apparently only required 
under certain conditions, such as during an innate immune 
response. As such, it provides a relatively tumour specific 
targeting opportunity. Clearly, further molecular studies 
are required so that strategic targeting can be achieved and 
drug resistance eliminated in esophageal cancer.
MATERIALS AND METHODS
Cell culture and reagents
Established human esophageal cancer cell 
lines OE19, OE21 and OE33 were obtained from the 
European Collection of Cell Cultures. KYSE450 and 
FLO-1 cells were from DSMZ (Deutsche Sammlung 
von Mikroorganismen und Zellkulturen GmbH). OE19, 
OE21, OE33 and FLO-1 cell lines were maintained in 
RPMI 1640 medium (Sigma R8758) and KYSE450 
cells were maintained in 50:50 RPMI 1640:F-12 HAMS 
medium (Sigma N6658). All cultures were supplemented 
with 1% penicillin/streptomycin (Gibco Life Technologies 
15070-063), 10 % (v/v) foetal calf serum (Sigma F7524) 
and maintained at 37 °C, 5 % CO2. All reagents were 
purchased from Sigma unless otherwise stated. Drugs used 
include rapamycin R8781, 5-fluorouracil (5-FU) F6627 
and valproic acid P4543.
siRNA transfection
Cells were reverse transfected with 20 nM gene 
specific siRNAs and non-specific scrambled controls 
(Dharmacon ISG15: L-004235-03-0005, UBE2L6: 
L-008569-00-0005, Non-targeting siRNA #1: D-001810-
01-20), using Lipofectamine 2000 transfection 
reagent (Life Technologies 11668500), according to 
manufacturer’s instructions.
Western blotting and antibodies
Total cellular protein extracts were prepared by 
trypsinization of cells and lysing in modified RIPA buffer 
(50 mM Tris HCl (pH 7.4), 150 mM NaCl, 0.25 % sodium 
deoxycholate, 1 % Igepal, 1 mM EDTA, 1x Pefabloc, 1x 
protease inhibitor cocktail, 1 mM Na3VO4, 1 mM NaF). All 
protein samples (30 or 45 μg) were separated on NuPAGE 
4–12 % Bis-Tris gels (Invitrogen Life Technologies 
NP0322) and electrophoretically transferred onto PVDF 
membrane using the iBlot gel transfer system (Invitrogen 
IB1001). Membranes were incubated with anti-LC3 (MBL 
PD014), anti-UBEL26 (Abcam AP2118a) or anti-ISG15 
(CST 2743S) antibodies overnight at 4 °C and with anti-
β-actin (loading control) (Sigma A5441) for one hour at 
room temperature. Proteins were visualized using relevant 
IR-Dye conjugated secondary antibodies (Rockland) on the 
Odyssey IR imaging system (Li-Cor, Cambridge, United 
Kingdom). For all Western blots – integrated intensities are 
representative of three independent experiments.
Cyto-ID autophagy detection kit
Trypsinized cells were stained with the Cyto-
ID autophagy detection kit (Enzo Life Sciences ENZ-
51031-K200) according to the manufacturer’s instructions. 
An increase in the number of autophagic vesicles is 
detected as an increase in fluorescence in the 488-2 
channel. Data was collected on the BD LSR II flow 
cytometer with BD FACS Diva acquisition software. 
Gating and overlay histograms were generated using 
Flowjo data analysis software.
Evaluation of morphology
Cells were cytospun and stained using pro-diff I and 
II (Braidwood Laboratories BAPROD1). Apoptotic cells 
were characterised based on the appearance of two or 
more of the following features: cell shrinkage, chromatin 
condensation, DNA degradation and fragmentation into 
‘apoptotic bodies’ within an intact plasma membrane. 
Cytospin images are representative of at least three 
independent experiments. Images were captured using 
a DP70 digital microscope camera and Olympus DP-
Soft823 version 3.2 software (Mason Technologies 
Dublin, Ireland).
Colony formation assay
Colony formation (clonogenic) assays were used 
to determine the ability of cells to recover from a drug 
treatment and re-establish colonies as a monolayer. Cells 
were transfected or treated and following drug removal, 
the cells were trypsinized and viable cells counted. 1,500 
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viable cells were reseeded into a well of a six-well plate 
(in triplicate). Cells were allowed to attach and grow for 
between 10 and 14 days. Following the recovery period, 
media was removed and following a PBS wash, cells 
were fixed in 96 % ethanol for 5 minutes and stained with 
Prodiff II (Braidwood Laboratories E310). Plates were 
scanned and quantified using the Odyssey IR imaging 
system (Li-Cor, Cambridge, United Kingdom). Results are 
presented as integrated intensity ± SEM (standard error 
of the mean) from at least three independent experiments.
Evaluation of caspase-3 activity by flow 
cytometry
Following fixation in 4 % PFA, cells were washed 
in a permeabilisation buffer (0.1 % Triton X-100, 0.1 % 
sodium azide, 10 mM HEPES, 4 % FCS, 150 mM NaCl) 
and incubated on ice with anti-active caspase-3 antibody 
(BD Biosciences 559565) for 1 hr followed by Alexa fluor 
488 secondary antibody (Life Technologies A11034). 
Samples were analysed using the BD LSR II flow cytometer 
and BD FACS Diva acquisition and analysis software.
Statistical analysis
Statistical analysis was carried out using GraphPad 
Prism 5 software. Means were compared using 
independent student t-tests (unpaired). The p-value was 
considered statistically significant when it was *p < 0.05, 
**p < 0.01, ***p < 0.0001.
Abbreviations
ISG15, Interferon stimulated gene 15; UBE2L6, 
Ubiquitin/ISG15 conjugating enzyme E2L6; MFI, 
Mean Fluorescence Intensity; IFN, Interferon; USP18, 
Ubiquitin-specific peptidase 18; LC3, Microtubule-
associated protein 1 light chain 3 alpha.
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